Pyxis Oncology (PYXS) Operating Margin (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Operating Margin of 165.75% for Q4 2025, up 76.33% quarter-over-quarter from 700.35% in Q2 2025.

Pyxis Oncology (PYXS) Operating Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Operating Margin for 2 consecutive years, with 165.75% the latest figure, recorded in Q4 2025.

In Q4 2025, Operating Margin changed N/A year-over-year to 165.75%; the TTM figure through Dec 2025 stood at 609.18% (down 5511.0% YoY), while the FY2025 annual figure was 609.18%, down 5511.0% from the prior year.
Operating Margin grew to 165.75% in Q4 2025 per PYXS's latest filing, from 700.35% in the prior quarter.
Across five years, Operating Margin topped out at 34.71% in Q1 2024 and bottomed at 700.35% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Vertex Pharmaceuticals	138.53 Bn	130.68 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.34 Bn	78.35 Bn	3.93 Bn	30.15%
3	Argenx Se	64.67 Bn	59.48 Bn	1.37 Bn	32.54%
4	Moderna	59.04 Bn	53.90 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.03 Bn	36.94 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.78 Bn	27.47 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.81 Bn	9.42 Bn	668.28 Mn	-35.57%
8	Insmed	27.21 Bn	26.05 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	26.99 Bn	26.15 Bn	-	19.75%
10	Pyxis Oncology	202.21 Mn	169.22 Mn	-	-

Download Data